Quest Diagnostics Files Definitive Proxy Materials

Ticker: DGX · Form: DEFA14A · Filed: Apr 11, 2025 · CIK: 1022079

Quest Diagnostics Inc DEFA14A Filing Summary
FieldDetail
CompanyQuest Diagnostics Inc (DGX)
Form TypeDEFA14A
Filed DateApr 11, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, governance, shareholder-meeting

TL;DR

Quest Diagnostics just dropped their proxy statement - time to vote!

AI Summary

Quest Diagnostics Incorporated filed a Definitive Additional Materials proxy statement on April 11, 2025. This filing is related to their annual meeting and likely contains information about executive compensation, director nominations, and other shareholder proposals. The company, previously known as Corning Clinical Laboratories Inc., is incorporated in Delaware and headquartered in Secaucus, NJ.

Why It Matters

This filing provides shareholders with crucial information needed to make informed decisions regarding company governance, executive pay, and voting on important matters at the upcoming annual meeting.

Risk Assessment

Risk Level: low — This is a routine proxy filing, not indicating any immediate financial distress or significant new risks.

Key Players & Entities

  • Quest Diagnostics Incorporated (company) — Registrant
  • Corning Clinical Laboratories Inc. (company) — Former company name
  • Secaucus, NJ (location) — Company headquarters
  • April 11, 2025 (date) — Filing date

FAQ

What type of filing is this DEFA14A for Quest Diagnostics?

This is a Definitive Additional Materials proxy statement filed on April 11, 2025.

What is the primary purpose of a DEFA14A filing?

A DEFA14A filing is a proxy statement used to solicit shareholder votes on various corporate matters, such as director elections and executive compensation.

When was Quest Diagnostics previously known by another name?

Quest Diagnostics was formerly known as Corning Clinical Laboratories Inc., with a name change date of September 3, 1996.

Where is Quest Diagnostics headquartered?

Quest Diagnostics is headquartered at 500 Plaza Drive, Secaucus, NJ 07094.

What is the filing fee status for this document?

Quest Diagnostics indicated that no fee was required for this filing.

Filing Details

This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 11, 2025 regarding QUEST DIAGNOSTICS INC (DGX).

View full filing on EDGAR

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.